Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Center LaboratoriesROCO:4123 -1.31%71 Piotroski F-Score is 5 as of Sep. 04, 2026, which is 25% above its 10-year median of 4.00. GuruFocus rates ROCO:4123 with a GF Score™ of 71/100 and a GF Value™ of NT$41.39 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 986 Drug Manufacturers companies, Center Laboratories ranks better than 61.36% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Center Laboratories has an F-score of 5 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Center Laboratories's Piotroski F-Score or its related term are showing as below:
ROCO:4123'
s Piotroski F-Score Range Over the Past 10 Years
Min: 1 Med: 4 Max: 9
Current: 5
During the past 13 years, the highest Piotroski F-Score of Center Laboratories was 9. The lowest was 1. And the median was 4.
Center Laboratories (ROCO:4123) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Center Laboratories Piotroski F-Score Related Terms
Center Laboratories Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Center Laboratories's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Center Laboratories's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Center Laboratories Piotroski F-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Center Laboratories's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Center Laboratories's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Jun26) TTM:
Last Year (Jun25) TTM:
Net Income was 2717.594 + 6782.627 + 1965.542 + -10446.745 = NT$1,019 Mil. Cash Flow from Operations was 46.61 + 94.701 + 120.811 + 21.035 = NT$283 Mil. Revenue was 359.107 + 399.513 + 465.976 + 432.063 = NT$1,657 Mil. Gross Profit was 143.692 + 167.577 + 217.06 + 188.601 = NT$717 Mil.
Average Total Assets from the begining of this year (Jun25)
to the end of this year (Jun26) was
(23673.776 + 25809.42 + 34628.122 + 37726.993 + 23966.166) / 5 = NT$29160.8954 Mil. Total Assets at the begining of this year (Jun25) was NT$23,674 Mil. Long-Term Debt & Capital Lease Obligation was NT$3,745 Mil. Total Current Assets was NT$4,425 Mil. Total Current Liabilities was NT$2,396 Mil.
Net Income was 273.31 + -763.547 + 549.14 + -726.536 = NT$-668 Mil.
Revenue was 392.486 + 448.554 + 378.859 + 378.711 = NT$1,599 Mil. Gross Profit was 182.105 + 211.156 + 163.258 + 146.731 = NT$703 Mil.
Average Total Assets from the begining of last year (Jun24)
to the end of last year (Jun25) was
(27049.569 + 26027.63 + 25537.175 + 25553.232 + 23673.776) / 5 = NT$25568.2764 Mil. Total Assets at the begining of last year (Jun24) was NT$27,050 Mil. Long-Term Debt & Capital Lease Obligation was NT$1,204 Mil. Total Current Assets was NT$2,592 Mil. Total Current Liabilities was NT$5,519 Mil.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Center Laboratories's current Net Income (TTM) was 1,019.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Center Laboratories's return on assets of this year was 0.04304417. Center Laboratories's return on assets of last year was -0.02468184.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Center Laboratories's gearing of this year was 0.12841461. Center Laboratories's gearing of last year was 0.04708495.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Center Laboratories's current ratio of this year was 1.84678878. Center Laboratories's current ratio of last year was 0.46971079.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Center Laboratories's number of shares in issue this year was 795.943. Center Laboratories's number of shares in issue last year was 794.577.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Center Laboratories's gross margin of this year was 0.43275653. Center Laboratories's gross margin of last year was 0.43991342.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Center Laboratories's asset turnover of this year was 0.06997865. Center Laboratories's asset turnover of last year was 0.05909928.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
1
+
0
+
0
+
1
+
0
+
0
+
1
=
5
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Center Laboratories has an F-score of 5 indicating the company's financial situation is typical for a stable company.
Center Laboratories (ROCO:4123) has a Piotroski F-Score of 5 as of Sep. 04, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Center Laboratories and its competitors. This is 25% above median its historical median of 4.00. Over the past decade, Center Laboratories' Piotroski F-Score has ranged from 1.00 to 9.00. According to the industry distribution chart, Center Laboratories ranks #381 out of 986 companies in the Drug Manufacturers industry, placing it in the top 38.6%.
Is Center Laboratories' Piotroski F-Score too high?
Center Laboratories' current Piotroski F-Score of 5 is 25% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 9.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Center Laboratories' value of 5 is 0% at this industry median. Based on the distribution chart, Center Laboratories ranks #381 out of 986 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Center Laboratories has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Center Laboratories' Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Center Laboratories ranks #381 out of 986 companies for Piotroski F-Score. This puts Center Laboratories in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Center Laboratories' value of 5 is 0% at this benchmark. Historically, Center Laboratories' own Piotroski F-Score has ranged from 1.00 to 9.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Center Laboratories has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 986 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Center Laboratories's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Center Laboratories and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Center Laboratories's current Piotroski F-Score is 5, which is 25% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Center Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Center Laboratories (ROCO:4123) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$41.39, compared to a current price of NT$30.15 — trading 27.2% below its estimated fair value. The current Piotroski F-Score is 5, which is 25% above median its 10-year median of 4.00 and 0% at the Drug Manufacturers industry median of 5.00. Center Laboratories' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Center Laboratories (ROCO:4123), the current Piotroski F-Score is 5 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Center Laboratories (ROCO:4123) Overvalued in 2026?
Based on GuruFocus' analysis, Center Laboratories stock appears to be undervalued.
The current stock price of NT$30.15 is trading 27.2% below its estimated GF Value™ of NT$41.39.
GuruFocus considers Center Laboratories to be Modestly Undervalued.
Key valuation signals for ROCO:4123:
Piotroski F-Score: 5 (25% above median its 10-year median of 4.00)
GF Value™: NT$41.39 vs. price of NT$30.15 (27.2% below fair value)
Industry Position: 0% at the Drug Manufacturers median (#381 of 986)
No single metric tells the full story. See the ROCO:4123 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Center Laboratories Inc is engaged in the manufacture and sale of various Western pharmaceuticals, including Western medicine manufacturing, wholesale, and retail. The Company operates through the following segments: Pharmaceutical Division, Biotechnology Venture Capital, and Glac Segment. The Pharmaceutical Division, which generates the majority of revenue, manufactures and sells various Western pharmaceuticals. The Biotechnology Venture Capital segment invests in domestic and foreign biotechnology undertakings, while the Glac Segment manufactures and sells probiotic products. The Company operates in Taiwan, Mainland China, and other regions, with Taiwan generating the majority of revenue.
71GF Score
Get the complete analysis for ROCO:4123
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4123 has been successfully added to your 
